Search Results - "Shirren, Joseph"

  • Showing 1 - 5 results of 5
Refine Results
  1. 1

    Pathophysiology of neratinib-induced diarrhea in male and female rats: microbial alterations a potential determinant by Secombe, Kate R., Ball, Imogen A., Shirren, Joseph, Wignall, Anthony D., Keefe, Dorothy M., Bowen, Joanne M.

    Published in Breast cancer (Tokyo, Japan) (2021)
    “…Background Neratinib is a potent irreversible pan-ErbB tyrosine kinase inhibitor, approved by the FDA for extended adjuvant treatment of HER2-positive breast…”
    Get full text
    Journal Article
  2. 2

    Irinotecan disrupts tight junction proteins within the gut: Implications for chemotherapy-induced gut toxicity by Wardill, Hannah R, Bowen, Joanne M, Al-Dasooqi, Noor, Sultani, Masooma, Bateman, Emma, Stansborough, Romany, Shirren, Joseph, Gibson, Rachel J

    Published in Cancer biology & therapy (01-02-2014)
    “…Chemotherapy for cancer causes significant gut toxicity, leading to severe clinical manifestations and an increased economic burden. Despite much research,…”
    Get full text
    Journal Article
  3. 3

    Targeting neratinib-induced diarrhea with budesonide and colesevelam in a rat model by Secombe, Kate R., Ball, Imogen A., Shirren, Joseph, Wignall, Anthony D., Finnie, John, Keefe, Dorothy, Avogadri-Connors, Francesca, Olek, Elizabeth, Martin, David, Moran, Susan, Bowen, Joanne M.

    Published in Cancer chemotherapy and pharmacology (01-03-2019)
    “…Purpose Neratinib is an irreversible pan-ErbB tyrosine kinase inhibitor used for the extended adjuvant treatment of early-stage HER2-positive breast cancer…”
    Get full text
    Journal Article
  4. 4

    Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report by Coller, Janet K., Bowen, Joanne M., Ball, Imogen A., Wardill, Hannah R., van Sebille, Ysabella Z. A., Stansborough, Romany L., Lightwala, Zenab, Wignall, Anthony, Shirren, Joseph, Secombe, Kate, Gibson, Rachel J.

    Published in Cancer chemotherapy and pharmacology (01-02-2017)
    “…Purpose Irinotecan-induced gut toxicity is mediated in part by Toll-Like receptor 4 (TLR4) signalling. The primary purpose of this preclinical study was to…”
    Get full text
    Journal Article
  5. 5

    Selective MMP Inhibition, Using AZD3342, to Reduce Gastrointestinal Toxicity and Enhance Chemoefficacy in a Rat Model by Gibson, Rachel J, van Sebille, Ysabella Z A, Wardill, Hannah R, Wignall, Anthony, Shirren, Joseph, Ball, Imogen A, Williams, Nicole, Wanner, Kiara, Bowen, Joanne M

    Published in Chemotherapy (Basel) (01-01-2018)
    “…The common cytotoxic mechanisms that underpin chemoefficacy and toxicity have hampered efforts to deliver effective supportive care interventions, particularly…”
    Get more information
    Journal Article